IAP-based biodegraders can convert necroptosis to apoptosis and eliminate cancer driving protein complexes
Details
Publication Year 2026-03-31,Volume 33,Issue #4,Page 553-570 e5
Journal Title
Cell Chemical Biology
Abstract
Targeted protein degradation holds significant therapeutic potential. Intrabodies, such as nanobodies and monobodies, can degrade intracellular proteins via fusion to E3 ubiquitin ligases. Here, we developed multi-targeting biodegrader intrabodies using the RING domain of inhibitor of apoptosis (IAP) proteins, or the IAP-binding motif from Smac/DIABLO. When fused to monobodies recognizing the necroptosis effector mixed lineage kinase domain-like pseudokinase (MLKL), IAP-based intrabodies degraded both MLKL and IAPs, blocking necroptosis and sensitizing cells to apoptosis. The potent degradative ability of the IAP RING was demonstrated via fusion to distinct intrabodies, with those targeting RAS enabling IAP and RAS proto-oncogenes to be concurrently eliminated. Quantitative proteomics of select IAP-based intrabodies revealed additional degradation of the BAF chromatin-remodelling complex, uncovering IAP and BAF co-dependencies in cancer. This work establishes IAP-based intrabodies as a modular class of protein biodegraders, whose multi-targeting capacity can enable the redirection of damaging necrotic cell death toward apoptosis, and the eradication of cancer-drivers.
Publisher
Cell Press
Keywords
Baf; Iap; Mlkl; Protac; Swi/snf; Smac-mimetic; apoptosis; biodegrader; intrabody; necroptosis
Research Division(s)
Cancer Biology and Stem Cells; Inflammation
PubMed ID
41923618
Open Access at Publisher's Site
https://doi.org/vince@wehi.edu.au
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2026-04-27 03:52:45
Last Modified: 2026-04-27 03:52:54
An error has occurred. This application may no longer respond until reloaded. Reload 🗙